Gist To Up Stake In Bio-Intermediair

1 September 1996

Dutch company Gist-Brocades says that it is likely it will increase its 20% minority interest in Bio-Intermediair International Holdings, the Groningen, Netherlands-based biopharmaceutical company.

However, it says that no further details on this will be given at this stage. Bio-Intermediair is an independent provider of manufacturing services, specializing in pilot to large-scale cell cultures and production of biopharmaceuticals for therapeutic applications. Gist-Brocades, with 1995 turnover of 1.84 billion guilders ($1.11 billion), is a leading producer of baker's yeast, penicillin and enzymes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight